Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (NASDAQ: SLP) is a leading developer of modeling and simulation software and consulting services that support drug discovery, development research, and regulatory submissions. The company collaborates with pharmaceutical organizations to implement a data-driven, strategic modeling methodology that begins in early discovery stages, extends through preclinical and clinical development, and continues into clinical trials and post-approval phases.
Simulations Plus, through its subsidiaries Cognigen Corporation and DILIsym Services, offers a suite of top-ranked, user-friendly software solutions. These include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more. These tools bridge data mining and compound library screening with QSAR models and PBPK/TK modeling and simulation in both animals and humans. The company's quantitative systems pharmacology approaches are widely recognized and licensed by regulatory agencies globally.
In addition to software development, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. The company’s operations are divided into two primary segments: software and services. The software segment generates the majority of the company’s revenue.
Over the past 20 years, Simulations Plus has consistently partnered with clients to reduce costs and accelerate research timelines. The company’s innovative technology and methodologies have earned it a reputation as a reliable partner in the pharmaceutical industry.
Latest News: Simulations Plus continues to make headlines with its innovative solutions and strategic partnerships. Stay updated with the latest developments and achievements of Simulations Plus on our news section.
Simulations Plus has launched GastroPlus® X (GPX™), marking a significant upgrade in PBPK/PBBM modeling and simulation software. This new platform offers advanced models, refined algorithms, and integrated machine learning, alongside an intuitive interface and streamlined workflows. GPX is designed to enhance productivity through ease-of-use and faster processing. The development involved extensive user testing and feedback, resulting in a flexible platform that supports diverse research needs. Notably, GPX includes unique features like true polypharmacy simulations and flexible deployment options, including cloud integration. Available for licensing now, GPX aims to expand Simulations Plus's global market reach.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
What does Simulations Plus, Inc. do?
What are the main products of Simulations Plus?
How does Simulations Plus support drug development?
Who uses Simulations Plus technology?
What are the primary segments of Simulations Plus’ operations?
Which subsidiaries are part of Simulations Plus?
How long has Simulations Plus been in operation?
Where is Simulations Plus headquartered?
Does Simulations Plus offer consulting services?
How can I stay updated on Simulations Plus’ latest news?
